Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W Deininger

Showing results (41-50 of 160) with videos related to

Pageof 16
Sort By:
Hemasphere|January 17, 2020
Children and Adolescents with Chronic Myeloproliferative Neoplasms: Still an Unmet Biological and Clinical Need?Tariq I Mughal, Michael W Deininger, Nicole Kucine, et al.
Blood Advances|March 30, 2019
Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendationsAmi B Patel, Erin M Pettijohn, Sameem M Abedin, et al.
Blood|December 9, 2004
RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518Denise K Walters, Eric P Stoffregen, Michael C Heinrich, et al.
Leukemia & Lymphoma|August 25, 2020
Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemiaKandice E Roberts, Michael W Deininger, Gerhard C Hildebrandt, et al.
The Journal of Clinical Investigation|December 16, 2010
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activityAmie S Corbin, Anupriya Agarwal, Marc Loriaux, et al.
Cancer Research|December 25, 2002
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)Paul La Rosée, Amie S Corbin, Eric P Stoffregen, et al.
Blood|February 11, 2003
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinibAmie S Corbin, Paul La Rosée, Eric P Stoffregen, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 5, 2021
Anticoagulation management post-transjugular intrahepatic portosystemic shunt in portal hypertension associated with myeloproliferative neoplasmsMouhamed Yazan Abou-Ismail, Josef T Prchal, Michael W Deininger, et al.
Biochemical Pharmacology|March 9, 2010
Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatmentSandra A Bright, Giuseppe Campiani, Michael W Deininger, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 4, 2025
KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic MastocytosisAndreas Reiter, Julien Rossignol, Michael W Deininger, et al.
Pageof 16

Showing results (41-50 of 160) with videos related to

Sort By:
Pageof 16
Hemasphere|January 17, 2020
Children and Adolescents with Chronic Myeloproliferative Neoplasms: Still an Unmet Biological and Clinical Need?Tariq I Mughal, Michael W Deininger, Nicole Kucine, et al.
Blood Advances|March 30, 2019
Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendationsAmi B Patel, Erin M Pettijohn, Sameem M Abedin, et al.
Blood|December 9, 2004
RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518Denise K Walters, Eric P Stoffregen, Michael C Heinrich, et al.
Leukemia & Lymphoma|August 25, 2020
Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemiaKandice E Roberts, Michael W Deininger, Gerhard C Hildebrandt, et al.
The Journal of Clinical Investigation|December 16, 2010
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activityAmie S Corbin, Anupriya Agarwal, Marc Loriaux, et al.
Cancer Research|December 25, 2002
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)Paul La Rosée, Amie S Corbin, Eric P Stoffregen, et al.
Blood|February 11, 2003
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinibAmie S Corbin, Paul La Rosée, Eric P Stoffregen, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 5, 2021
Anticoagulation management post-transjugular intrahepatic portosystemic shunt in portal hypertension associated with myeloproliferative neoplasmsMouhamed Yazan Abou-Ismail, Josef T Prchal, Michael W Deininger, et al.
Biochemical Pharmacology|March 9, 2010
Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatmentSandra A Bright, Giuseppe Campiani, Michael W Deininger, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 4, 2025
KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic MastocytosisAndreas Reiter, Julien Rossignol, Michael W Deininger, et al.
Pageof 16